Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time
Phase III data for Medivation's MDV3100 suggest the prostate cancer drug stands to unseat J&J’s market leader Zytiga in many of the disease settings.
You may also be interested in...
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.
A significant discount from Amgen has left NICE more than happy to pass Xgeva, but it still found economic grounds to reject the company’s application for a prostate cancer indication.
Medivation/Astellas’ Xtandi was approved barely a month after FDA announced it had accepted its NDA for post-chemo castration-resistant metastatic prostate cancer, and the newly approved androgen blocker appears to have what it takes to unseat J&J’s market leader Zytiga.